DOW JONES21,052.53-360.91 -1.69%
S&P 5002,488.65-38.25 -1.51%
NASDAQ7,373.08-114.23 -1.53%

Xeris Pharmaceuticals Q4 EPS $(1.23) Misses $(1.13) Estimate, Sales $1.6M Beat $660K Estimate

Xeris Pharmaceuticals (NASDAQ:XERS) reported quarterly losses of $(1.23) per share which missed the analyst consensus estimate of $(1.13) by 8.85 percent. This is a 25.51 percent decrease over losses of $(0.98) per share

Benzinga · 03/11/2020 10:02

Xeris Pharmaceuticals (NASDAQ:XERS) reported quarterly losses of $(1.23) per share which missed the analyst consensus estimate of $(1.13) by 8.85 percent. This is a 25.51 percent decrease over losses of $(0.98) per share from the same period last year. The company reported quarterly sales of $1.6 million which beat the analyst consensus estimate of $660 thousand by 142.42 percent. This is a 99.75 percent increase over sales of $801 thousand the same period last year.